It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
After a diagnosis of colorectal cancer (CRC), approximately 50% of patients will present distant metastasis. Although significant progress has been made in treatments, most of them will die from the disease. We investigated the predictive and prognostic potential of APC11, the catalytic subunit of APC/C, which has never been examined in the context of CRC. The expression of APC11 was assessed in CRC cell lines, in tissue microarrays (TMAs) and in public datasets. Overexpression of APC11 mRNA was associated with chromosomal instability, lymphovascular invasion and residual tumor. Regression models accounting for the effects of well-known protein markers highlighted association of APC11 protein expression with residual tumor (odds ratio: OR = 6.51; 95% confidence intervals: CI = 1.54–27.59; P = 0.012) and metastasis at diagnosis (OR = 3.87; 95% CI = 1.20–2.45; P = 0.024). Overexpression of APC11 protein was also associated with worse distant relapse-free survival (hazard ratio: HR = 2.60; 95% CI = 1.26–5.37; P = 0.01) and worse overall survival (HR = 2.69; 95% CI = 1.31–5.51; P = 0.007). APC11 overexpression in primary CRC thus represents a potentially novel theranostic marker of metastatic CRC.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Centre Léon Bérard, Département de Santé Publique, Lyon, France; CNRS UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Lyon, France
2 Centre Léon Bérard, Service d’Anatomopathologie, Lyon, France
3 INRIA Grenoble-Rhône-Alpes, 655 Avenue de l’Europe, Montbonnot, Saint Martin, France; Synergie Lyon Cancer, Plateforme de Bioinformatique ‘Gilles Thomas’ Centre Léon Bérard, Lyon, France
4 Centre Léon Bérard, Lyon, France; INSERM U1052, Cancer Research Center of Lyon, Lyon, France; CNRS UMR 5286, Cancer Research Center of Lyon, Lyon, France; Université de Lyon, Lyon, France; Université Lyon1, ISPB, Lyon, France; LabEx DEVweCAN, Université de Lyon, Lyon, France; Hôpital de la Croix Rousse, Hospices Civils de Lyon, Lyon, France
5 Centre Léon Bérard, Département de Santé Publique, Lyon, France; Hospices Civils de Lyon, Hôpital Edouard Herriot, Service d’Hygiéne, Epidémiologie et Prévention, Lyon, France
6 Centre Léon Bérard, Lyon, France
7 Centre Léon Bérard, Lyon, France; INSERM U1052, Cancer Research Center of Lyon, Lyon, France; CNRS UMR 5286, Cancer Research Center of Lyon, Lyon, France; Université de Lyon, Lyon, France; Université Lyon1, ISPB, Lyon, France; LabEx DEVweCAN, Université de Lyon, Lyon, France
8 Centre Léon Bérard, Département de Santé Publique, Lyon, France; CNRS UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Lyon, France; Université de Lyon, Lyon, France